DX-2930

Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application
Endpoints
Thu, 05/18/17 - 09:38 am
Shire
lanadelumab
DX-2930
HAE
Cinryze
Dyax
Dyax banks on drug designation news
Bizjournals.com
Tue, 07/7/15 - 12:28 pm
Dyax
DX-2930
HAE
hereditary angiodema
Dyax's Threat to $630,000 Shire Drug Makes It a Target
Bloomberg
Thu, 06/11/15 - 10:13 am
Shire
Dyax
DX-2930
HAE
hereditary angiodema
Cinryze
Dyax shares jump on drug study, FDA fast-track status
Marketwatch
Tue, 03/31/15 - 05:53 pm
Dyax
FDA
fast track
DX-2930
hereditary angiodema
This Company Is Focused on Delivering Value to Patients and Shareholders
Motley Fool
Sun, 10/6/13 - 09:19 am
Dyax
DX-2930
angioedema